Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.66 |
| ▸ | KHK | P50053 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | C1S | P09871 | 3/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485626 | 1.00 | BPTF (0.66) | BPTFKHKHTR2BHTR2AHTR2C | |
| SCHEMBL1349684 | 1.00 | BPTF (0.66) | BPTFKHKHTR2BHTR2AHTR2C | |
| SCHEMBL30818756 | 0.90 | BPTF (0.58) | BPTFKHKHTR2BHTR2AHTR2C | |
| SCHEMBL29991273 | 0.90 | BPTF (0.60) | BPTFHTR2BHTR2AHTR2CC1S | |
| SCHEMBL377392 | 0.90 | BPTF (0.60) | BPTFHTR2BHTR2AHTR2CC1S | |
| Hydrochloric Acid SCHEMBL376509 | 0.88 | BPTF (0.59) | BPTFHTR2BHTR2AHTR2CC1S | |
| SCHEMBL1349699 | 0.80 | NOTUM (0.60) | BPTFKHKHRH4NOTUM | |
| SCHEMBL5710409 | 0.80 | BPTF (0.61) | BPTFMLYCDNOTUM | |
| SCHEMBL6488653 | 0.80 | NOTUM (0.60) | BPTFKHKHRH4NOTUM | |
| SCHEMBL21460258 | 0.80 | KHK (0.47) | BPTFKHKHTR2BHRH4VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063078-B2 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | GLAXOSMITHKLINE LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2298757-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1425277-B8 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-6939891-B2 | Nitrogen compounds such as N-(4-Fluorophenyl)-N'-[(R)-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea, used as analgesics | SMITHKLINE BEECHAM, PLC (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1425277-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SmithKline Beecham P.L.C. (GB) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004024710-A1 | UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| EP-1392651-A1 | HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003022809-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002090326-A1 | HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | BPTF 3496/4885KHK 2931/4885HTR2B 666/4885 |
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | TRPV1, UTS2R, GPR17 | BPTF 3932/4885KHK 2636/4885HTR2B 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.